Company profile: Elektrofi
1.1 - Company Overview
Company description
- Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
Products and services
- Formulation Development Services: Delivers subcutaneous-focused development of biologic therapies with process development, formulation, analytics, and innovation in collaboration with strategic partners
- Hypercon™: Engineers a microparticle-based platform that enables development of low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery
- Partnership Programs: Offers formulation-technology–based collaboration with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies using Elektrofi's formulation technology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elektrofi
MannKind
HQ: United States
Website
- Description: Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MannKind company profile →
Cellectar Biosciences
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectar Biosciences company profile →
Elucida Oncology
HQ: United States
Website
- Description: Provider of targeted C'Dot Drug Conjugates (CDCs) for patients with primary solid tumor and metastatic cancer. Ultra-small CDC nanoparticles penetrate tumors, carry high drug payloads, and clear rapidly via kidneys (Target or Clear) to reduce systemic exposure and off-target toxicity. Pipeline includes ELU001, a CDC targeting folate receptor alpha in clinical trials; ELU002; and surface chemistry for toxic payloads and radionuclides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elucida Oncology company profile →
Corsair Pharma
HQ: United States
Website
- Description: Provider of a transdermal treprostinil prodrug patch for pulmonary arterial hypertension (PAH), designed to deliver consistent blood levels and reduce the need for invasive administration. Develops transformative solutions to improve the therapeutic profile of medications and provide superior treatment for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corsair Pharma company profile →
H&T Presspart
HQ: United Kingdom
Website
- Description: Provider of drug delivery devices and manufacturing services for asthma and COPD, offering metered-dose inhalation devices and components (actuators, dose counters), dry powder inhalers including PowdAir Plus, comprehensive drug delivery device development from design to manufacturing, high-precision injection moulding, automated multi-component assembly, and deep drawing of metal components such as MDI cans.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full H&T Presspart company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elektrofi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elektrofi
2.2 - Growth funds investing in similar companies to Elektrofi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elektrofi
4.2 - Public trading comparable groups for Elektrofi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →